Biosight is a clinical-stage company focused on developing aspacytarabine (BST-236), a novel antimetabolite, as a therapy for elderly chemotherapy-ineligible AML patients.
Arkin Entry Stage
Phase 1
Status
M&A
Location
Tel-Aviv
Let’s get in touch!
